Sickle cell patients often face challenges when implementing their care plans. Columnist Mary Shaniqua describes what good ...

Nearly all the patients with severe SCD treated with the gene-editing therapy reni-cel remained free of VOEs for up to two ...

Data from a Phase 2/3 trial shows etavopivat may reduce the incidence of vaso-occlusive crises and raise levels of hemoglobin ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

When a sickle cell pain crisis landed her in the hospital, columnist Mary Shaniqua soon identified the cause: getting two vaccines at once.

Sickle cell disease can manifest as both a visible and invisible illness, depending on the individual and their unique ...

The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...

Kanglin Biotechnology has raised $20 million in financing to advance the development of KL003, an experimental gene therapy ...

Mary Shaniqua is a sickle cell patient (HbSS) living in the United Kingdom. She was diagnosed with sickle cell at 18 months old and uses “Shaniqua’s Sickle Chronicles” to narrate her experiences, to ...